These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 22863599)

  • 1. Dopamine D₂-agonist rotigotine effects on cortical excitability and central cholinergic transmission in Alzheimer's disease patients.
    Martorana A; Di Lorenzo F; Esposito Z; Lo Giudice T; Bernardi G; Caltagirone C; Koch G
    Neuropharmacology; 2013 Jan; 64():108-13. PubMed ID: 22863599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine modulates cholinergic cortical excitability in Alzheimer's disease patients.
    Martorana A; Mori F; Esposito Z; Kusayanagi H; Monteleone F; Codecà C; Sancesario G; Bernardi G; Koch G
    Neuropsychopharmacology; 2009 Sep; 34(10):2323-8. PubMed ID: 19516251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients.
    Koch G; Di Lorenzo F; Bonnì S; Giacobbe V; Bozzali M; Caltagirone C; Martorana A
    Neuropsychopharmacology; 2014 Oct; 39(11):2654-61. PubMed ID: 24859851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Rotigotine vs Placebo on Cognitive Functions Among Patients With Mild to Moderate Alzheimer Disease: A Randomized Clinical Trial.
    Koch G; Motta C; Bonnì S; Pellicciari MC; Picazio S; Casula EP; Maiella M; Di Lorenzo F; Ponzo V; Ferrari C; Scaricamazza E; Caltagirone C; Martorana A
    JAMA Netw Open; 2020 Jul; 3(7):e2010372. PubMed ID: 32667654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
    Perez-Lloret S; Rey MV; Ratti PL; Rascol O
    Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Local effects of transdermal treatment with rotigotine].
    Bermejo PE; Zea MA; Alba-Alcántara L; Ruiz-Huete C
    Rev Neurol; 2013 Apr; 56(7):359-62. PubMed ID: 23520004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rotigotine: Parkinson's disease: a step backward.
    Prescrire Int; 2008 Apr; 17(94):60. PubMed ID: 18516813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug safety evaluation of rotigotine.
    Sprenger FS; Seppi K; Poewe W
    Expert Opin Drug Saf; 2012 May; 11(3):503-12. PubMed ID: 22468676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rotigotine and restless legs syndrome: new indication. The worst dopamine agonist. Just as unsatisfactory; defective design.
    Prescrire Int; 2009 Oct; 18(103):197. PubMed ID: 19882782
    [No Abstract]   [Full Text] [Related]  

  • 10. Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K; Lyons KE
    Pharmacotherapy; 2009 Dec; 29(12):1452-67. PubMed ID: 19947805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabergoline reverses cortical hyperexcitability in patients with restless legs syndrome.
    Nardone R; Ausserer H; Bratti A; Covi M; Lochner P; Marth R; Tezzon F
    Acta Neurol Scand; 2006 Oct; 114(4):244-9. PubMed ID: 16942543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled trial of rotigotine monotherapy in early Parkinson's disease.
    Parkinson Study Group
    Arch Neurol; 2003 Dec; 60(12):1721-8. PubMed ID: 14676046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rotigotine transdermal patches (Neupro) for the treatment of Parkinson's disease.
    Chatsis V
    Issues Emerg Health Technol; 2008 Feb; (112):1-6. PubMed ID: 18354859
    [No Abstract]   [Full Text] [Related]  

  • 14. [Continued Use of Rotigotine Transdermal Patches for Parkinson Disease].
    Yasutaka Y; Fujioka S; Shibaguchi H; Imakyure O; Washiyama A; Tsuboi Y; Futagami K
    Brain Nerve; 2016 Jun; 68(6):655-60. PubMed ID: 27279164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.
    Zesiewicz TA; Martinez-Martin P
    Expert Rev Neurother; 2013 Dec; 13(12):1329-42. PubMed ID: 24236902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotigotine transdermal system for the treatment of Parkinson's disease.
    Pham DQ; Nogid A
    Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal rotigotine (Neupro) for Parkinson's disease.
    Med Lett Drugs Ther; 2007 Aug; 49(1268):69-70. PubMed ID: 17712291
    [No Abstract]   [Full Text] [Related]  

  • 18. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
    Splinter MY
    Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotigotine Schwarz Pharma.
    Mucke HA
    IDrugs; 2003 Sep; 6(9):894-9. PubMed ID: 12964070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-dopa modulates motor cortex excitability in Alzheimer's disease patients.
    Martorana A; Stefani A; Palmieri MG; Esposito Z; Bernardi G; Sancesario G; Pierantozzi M
    J Neural Transm (Vienna); 2008 Sep; 115(9):1313-9. PubMed ID: 18594753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.